Similar articles

• Olutasidenib: First Approval.

  Kang C. Kang C. Drugs. 2023 Mar;83(4):341-346. doi: 10.1007/s40265-023-01844-1. Drugs. 2023. PMID: 36848032 Review.
• FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.

  Norsworthy KJ, Luo L, Hsu V, Gudi R, Dorff SE, Przepiorka D, Deisseroth A, Shen YL, Sheth CM, Charlab R, Williams GM, Goldberg KB, Farrell AT, Pazdur R. Norsworthy KJ, et al. Clin Cancer Res. 2019 Jun 1;25(11):3205-3209. doi: 10.1158/1078-0432.CCR-18-3749. Epub 2019 Jan 28. Clin Cancer Res. 2019. PMID: 30692099
• Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

  Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. Watts JM, et al. Lancet Haematol. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7. Epub 2022 Nov 10. Lancet Haematol. 2023. PMID: 36370742 Clinical Trial.
• Evaluating ivosidenib for the treatment of acute myeloid leukemia.

  Donker ML, Ossenkoppele GJ. Donker ML, et al. Expert Opin Pharmacother. 2020 Dec;21(18):2205-2213. doi: 10.1080/14656566.2020.1806822. Epub 2020 Aug 18. Expert Opin Pharmacother. 2020. PMID: 32808831 Review.
• Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.

  Prakash C, Fan B, Ke A, Le K, Yang H. Prakash C, et al. Cancer Chemother Pharmacol. 2020 Nov;86(5):619-632. doi: 10.1007/s00280-020-04148-3. Epub 2020 Sep 25. Cancer Chemother Pharmacol. 2020. PMID: 32978634